## Nicole Bernard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10574250/publications.pdf

Version: 2024-02-01

1040056 1199594 12 619 9 12 citations h-index g-index papers 12 12 12 944 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. Journal of Virology, 2015, 89, 545-551.	3.4	173
2	Receptor-Ligand Requirements for Increased NK Cell Polyfunctional Potential in Slow Progressors Infected with HIV-1 Coexpressing KIR3DL1*h/*y and HLA-B*57. Journal of Virology, 2011, 85, 5949-5960.	3.4	90
3	eEF2 and Ras-GAP SH3 domain-binding protein (G3BP1) modulate stress granule assembly during HIV-1 infection. Nature Communications, 2014, 5, 4819.	12.8	76
4	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. Journal of Virological Methods, 2014, 208, 107-114.	2.1	62
5	Prevalence of Antibodies Reactive with a 64 kDa Eye Muscle Membrane Antigen in Thyroid-Associated Ophthalmopathy. Thyroid, 1991, 1, 207-213.	4.5	48
6	The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. BMC Infectious Diseases, 2017, 17, 611.	2.9	45
7	A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. Aids, 2011, 25, 731-739.	2.2	41
8	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Scientific Reports, 2016, 6, 22902.	3.3	38
9	Significance of Antibodies Reactive with a 64 kDa Eye Muscle Membrane Antigen in Patients with Thyroid Autoimmunity. Thyroid, 1992, 2, 197-202.	4.5	32
10	KIR3DL1 alleles and their epistatic interactions with human leukocyte antigen class I influence resistance and susceptibility to HIV-1 acquisition in the Pumwani sex worker cohort. Aids, 2018, 32, 841-850.	2.2	6
11	Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction. Frontiers in Immunology, 2021, 12, 673061.	4.8	5
12	Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173. Trials in Vaccinology, 2012, 1, 21-26.	1.2	3